구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | immune evaluation (immune evaluation) Istituto Clinico Humanitas·Oligorecurrent and Oligoprogressiv… 61 trials |
|---|---|
Overview Program | immune evaluation |
Overview Company | Istituto Clinico Humanitas |
Overview Modality | CGT |
Overview Target | Oligorecurrent and Oligoprogressive Pros |
Overview Indication | Oligorecurrent and Oligoprogressive Prostate Cancer Patients |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | retroviral therapy when used with two nucleoside reverse transcriptase inhibitors (NRTIs) |
MoA Mechanism | of B-cell depleting agents, the clinical utility and adverse effects of these therapies, and the relevance of systematic and serial laboratory immune monitoring in identifying patients at risk for developing immunologic |
MoA Biomarker | biomarkers |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | The Ave-Rec Trial: Phase II Trial of PDL1/PD1 Blockade with Avelumab after Chemoradiotherapy for Locally Advanced Resectable T3B-4/N1-2 Rectal Cancer.. Long-course chemoradiotherapy (LCCRT) for locally advanced rectal cancer (LARC) achieves a pathologic complete response (pCR) in approximately 10% to 30% of cases. Radiotherapy exerts both immunostimulatory and immunosuppressive effects. Inhibition… |
Toxicology CRS | Reported |
Clinical Safety signal | The Ave-Rec Trial: Phase II Trial of PDL1/PD1 Blockade with Avelumab after Chemoradiotherapy for Locally Advanced Resectable T3B-4/N1-2 Rectal Cancer.. Long-course chemoradiotherapy (LCCRT) for locally advanced rectal cancer (LARC) achieves a pathologic complete response (pCR) in approximately 10% to 30% of cases. Radiotherapy exerts both immunostimulatory and immunosuppressive effects. Inhibition… |
Clinical Selected reported efficacy | ORR 37.5% |
Clinical Reported ORR | 37.5% |
Clinical Result source | ClinicalTrials.gov NCT05228470 |
Clinical Program phase | PRECLINICAL |
Clinical Trial ref | NCT05228470 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | immune evaluation (immune evaluation) Istituto Clinico Humanitas·Oligorecurrent and Oligoprogressiv… 61 trials |
|---|---|
Overview Program | immune evaluation |
Overview Company | Istituto Clinico Humanitas |
Overview Modality | CGT |
Overview Target | Oligorecurrent and Oligoprogressive Pros |
Overview Indication | Oligorecurrent and Oligoprogressive Prostate Cancer Patients |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | retroviral therapy when used with two nucleoside reverse transcriptase inhibitors (NRTIs) |
MoA Mechanism | of B-cell depleting agents, the clinical utility and adverse effects of these therapies, and the relevance of systematic and serial laboratory immune monitoring in identifying patients at risk for developing immunologic |
MoA Biomarker | biomarkers |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | The Ave-Rec Trial: Phase II Trial of PDL1/PD1 Blockade with Avelumab after Chemoradiotherapy for Locally Advanced Resectable T3B-4/N1-2 Rectal Cancer.. Long-course chemoradiotherapy (LCCRT) for locally advanced rectal cancer (LARC) achieves a pathologic complete response (pCR) in approximately 10% to 30% of cases. Radiotherapy exerts both immunostimulatory and immunosuppressive effects. Inhibition… |
Toxicology CRS | Reported |
Clinical Safety signal | The Ave-Rec Trial: Phase II Trial of PDL1/PD1 Blockade with Avelumab after Chemoradiotherapy for Locally Advanced Resectable T3B-4/N1-2 Rectal Cancer.. Long-course chemoradiotherapy (LCCRT) for locally advanced rectal cancer (LARC) achieves a pathologic complete response (pCR) in approximately 10% to 30% of cases. Radiotherapy exerts both immunostimulatory and immunosuppressive effects. Inhibition… |
Clinical Selected reported efficacy | ORR 37.5% |
Clinical Reported ORR | 37.5% |
Clinical Result source | ClinicalTrials.gov NCT05228470 |
Clinical Program phase | PRECLINICAL |
Clinical Trial ref | NCT05228470 |
추천 비교
추천 비교